ZURICH (Reuters) – The United States Food and Drugs Administration (FDA) has granted a priority review for Roche’s Tecentriq treatment for people suffering with early, non-small-cell lung cancer, the Swiss company said on Tuesday.
The FDA is due to decide on approval by Dec. 1 for the use of Tecentriq as an adjuvnt treatment, where a substance is used to increase the efficacy or potency of certain drugs, Roche said.
(Reporting by John Revill; Editing by Christian Schmollinger)
Canucks overcome 3-goal deficit to stun Oilers 5-4 in Game 1
Jalen Brunson returns from foot injury, sparks Knicks past Pacers for 2-0 lead in East semifinals
Aleksander Barkov scores twice, Panthers rout Bruins 6-1 in Game 2 to tie series
Jalen Brunson returns for NY in 2nd half of Game 2 vs. Pacers, then Anunoby exits with injury
Jokic wins NBA’s MVP award, his 3rd in 4 seasons. Gilgeous-Alexander and Doncic round out top 3
First shipment of aid to the US-built floating pier in Gaza departs from Cyprus
Yemen’s Houthi rebels claim 2 attacks in Gulf of Aden as Iran official renews nuclear bomb threats
Guns are being stolen from cars at triple the rate they were 10 years ago, a report finds
Japan Fisheries Agency proposes allowing commercial catching of fin whales
Air Vanuatu cancels flights and considers bankruptcy protection
Kenya’s public hospital doctors sign agreement to end national strike after almost 2 months
How a Texas man is testing out-of-state abortions by asking a court to subpoena his ex-partner
Underpaid and overworked. Colleges, universities having trouble hiring, retaining athletic trainers
Steward Health Care says it is selling the 30+ hospitals it operates nationwide
